Avanir Pharma settles Nuedexta patent litigation with Actavis

3 September 2013

USA-based Avanir Pharmaceuticals (Nasdaq: AVNR) says that it has entered into a settlement agreement with Actavis South Atlantic and parent Actavis (NYSE: ACT) to resolve pending patent litigation in response to Actavis' Abbreviated New Drug Application seeking approval to market generic versions of Avanir's Nuedexta (dextromethorphan hydrobromide/quinidine sulfate) capsules.

Nuedexta was launched in the USA for the treatment of pseudobulbar affect (pathological crying or laughing) in late January 2011, and was recently approved for this indication in Europe (The Pharma Letter June 26).

The accord grants Actavis the right to begin selling a generic version of Nuedexta on July 30, 2026, or earlier under certain circumstances. The companies have also agreed to file a stipulation and order of dismissal with the US District Court for the District of Delaware which will conclude this litigation with respect to Actavis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK